Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation
Status:
Terminated
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
During SARS-Cov2 infection with serious respiratory implication and high systemic
inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe
cases might reduce inappropriate systemic inflammatory response, improve breathing and
decrease occurrence or duration of ARDS and associated mortality.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborators:
Assistance Publique Hopitaux De Marseille Hôpital d'instruction des armées Sainte-Anne